Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme.

about

Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme.

Item

http://www.wikidata.org/entity/Q53788954

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Severe periocular bleeding ind ...... rrent glioblastoma multiforme.

@en

Severe periocular bleeding ind ...... rrent glioblastoma multiforme.

@nl

type

Item

label

Severe periocular bleeding ind ...... rrent glioblastoma multiforme.

@en

Severe periocular bleeding ind ...... rrent glioblastoma multiforme.

@nl

prefLabel

Severe periocular bleeding ind ...... rrent glioblastoma multiforme.

@en

Severe periocular bleeding ind ...... rrent glioblastoma multiforme.

@nl

P1476

Severe periocular bleeding ind ...... rrent glioblastoma multiforme.

@en

P2093

Derya K Salim

http://www.w3.org/2001/XMLSchema#string

Fatma Yalçin Müsri

http://www.w3.org/2001/XMLSchema#string

Gökhan Tazegül

http://www.w3.org/2001/XMLSchema#string

Hasan Mutlu

http://www.w3.org/2001/XMLSchema#string

Hasan Ş Coşkun

http://www.w3.org/2001/XMLSchema#string

Melek K Eryılmaz

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Optic neuropathy in patients with glioblastoma receiving bevacizumab.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration

Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.

Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature.

P304

392-395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155216643858

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27105898

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab